This document describes the state of knowledge of the adverse outcome pathway (AOP) for skin sensitisation initiated by covalent binding to proteins, assesses the weight-of-evidence supporting the AOP, identifies the key events, and identifies databases containing test results related to those key events. AOPs can be incorporated into chemical categories-based assessments or integrated approaches for testing and assessment.